

PROVIDER QUICK POINTS

PROVIDER INFORMATION



November 23, 2022

Commercial Pharmacy Benefit Exclusion for Cimerli™, Skysona®, Spevigo®, and Xenpozyme™

Effective **November 23, 2022**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Cimerli™ (ranibizumab-eqrn) injection for intravitreal use
Skysona® (elivaldogene autotemcel) suspension for intravenous (IV) infusion
Spevigo® (spesolimab-sbzo) solution for intravenous (IV) infusion
Xenpozyme™ (olipudase alfa-rpcp) lyophilized powder for reconstitution for intravenous (IV) infusion

Products Impacted

This applies to the commercial line of business.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.